NasdaqGS:NXTC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has NextCure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NXTC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-5.0%

NXTC

-1.2%

US Biotechs

-1.1%

US Market


1 Year Return

-59.5%

NXTC

30.7%

US Biotechs

15.6%

US Market

Return vs Industry: NXTC underperformed the US Biotechs industry which returned 30.7% over the past year.

Return vs Market: NXTC underperformed the US Market which returned 15.6% over the past year.


Shareholder returns

NXTCIndustryMarket
7 Day-5.0%-1.2%-1.1%
30 Day30.4%1.3%4.2%
90 Day22.7%-2.5%6.3%
1 Year-59.5%-59.5%33.0%30.7%18.2%15.6%
3 Yearn/a19.6%13.6%39.6%30.4%
5 Yearn/a8.7%1.0%79.5%59.2%

Price Volatility Vs. Market

How volatile is NextCure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NextCure undervalued compared to its fair value and its price relative to the market?

0.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NXTC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NXTC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NXTC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: NXTC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NXTC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NXTC is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is NextCure forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-27.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NXTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NXTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NXTC's revenue (54.8% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: NXTC's revenue (54.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NXTC is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has NextCure performed over the past 5 years?

10.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: NXTC is currently unprofitable.

Growing Profit Margin: NXTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NXTC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NXTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NXTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: NXTC has a negative Return on Equity (-7.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is NextCure's financial position?


Financial Position Analysis

Short Term Liabilities: NXTC's short term assets ($315.1M) exceed its short term liabilities ($8.4M).

Long Term Liabilities: NXTC's short term assets ($315.1M) exceed its long term liabilities ($3.2M).


Debt to Equity History and Analysis

Debt Level: NXTC's debt to equity ratio (1.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if NXTC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NXTC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NXTC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 71.5% each year


Next Steps

Dividend

What is NextCure current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NXTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NXTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NXTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Michael Richman (59 yo)

5yrs

Tenure

US$625,679

Compensation

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since October 2015. Mr. Richman served as the Chief Executive Officer and P ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD625.68K) is below average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Richman
Co-Founder5yrsUS$625.68k1.4%
$ 4.2m
Solomon Langermann
Chief Scientific Officer1.83yrsUS$459.11k0.14%
$ 408.2k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Steven Cobourn
Chief Financial Officer2.75yrsUS$1.01m0%
$ 0
Timothy Mayer
Chief Operating Officer1yrno datano data
Linda Liu
Senior Vice President of Research1.83yrsno data0.20%
$ 603.7k
James Bingham
Chief Development Officer1.83yrsno data0.32%
$ 952.3k

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: NXTC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Richman
Co-Founder5yrsUS$625.68k1.4%
$ 4.2m
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Elaine Jones
Independent Director4.83yrsUS$244.55k0%
$ 0
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
David Kabakoff
Independent Chairman of the Board4.83yrsUS$266.81k0.23%
$ 680.2k
Stephen Webster
Independent Director1.5yrsUS$249.07k0%
$ 0
Chau Khuong
Independent Director4.83yrsUS$245.19k0%
$ 0
Briggs Morrison
Independent Director1.5yrsUS$248.61k0%
$ 0
Garry Nicholson
Independent Director0.58yrno datano data
Stephen Miller
Member of Scientific Advisory Boardno datano datano data
Xiaoxing Xu
Independent Director1.92yrsUS$241.97k0%
$ 0
Ethan Shevach
Member of Scientific Advisory Boardno datano datano data

3.4yrs

Average Tenure

61yo

Average Age

Experienced Board: NXTC's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.3%.


Top Shareholders

Company Information

NextCure, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NextCure, Inc.
  • Ticker: NXTC
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$301.152m
  • Shares outstanding: 27.55m
  • Website: https://www.nextcure.com

Number of Employees


Location

  • NextCure, Inc.
  • 9000 Virginia Manor Road
  • Suite 200
  • Beltsville
  • Maryland
  • 20705
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NXTCNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2019
2USMUN (Boerse Muenchen)YesCommon StockDEEURMay 2019
2USDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2019

Biography

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:05
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.